A number of things to consider:
- The Astra Zeneca deal with Accent Therapeutics was signed before the Cancer Cell paper with City of Hope findings was published
- Accent were formed with a focus on METTL3 (not FTO)
- The cancer cell paper buried the name of the drug used - labelling Bisantrene with a code name CS1. This had the effect that most of the news on the interwebs was referring to the compound as CS1 - not Bisantrene.
- I don't think Accent would make a song and dance about another research group identifying a competing drug just weeks after the deal with AstraZeneca was signed ( due to possible escape clauses for AstraZeneca in the early parts of the deal )
RAC media coverage, page-181
-
- There are more pages in this discussion • 2,116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
0.010(0.56%) |
Mkt cap ! $304.2M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.80 | $1.78 | $106.4K | 59.41K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 600 | $1.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.83 | 10000 | 2 |
View Market Depth
| Last trade - 15.57pm 30/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |